Interleukin Genetics to Present at Rodman & Renshaw
05/13/2008
Interleukin Genetics to Present at Rodman & Renshaw
5th Annual Global Healthcare Conference
Waltham, MA - May 13, 2008 - Interleukin Genetics, Inc. (AMEX:ILI) announced today that Lewis H. Bender, Chief Executive Officer, will present at the Rodman and Renshaw 5th Annual Global Healthcare Conference on Monday May 19, 2008, at 10:00 a.m. CEST (4:00 a.m. EDT). The conference will be held at Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco.
A live audio webcast of the presentation will be available on the Investors section of the Company’s website, www.wsw.com.
A replay of the presentation will be available on the Interleukin Genetics website for 14 days following the presentation.
About Interleukin Genetics
Interleukin Genetics, Inc. (AMEX: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals®, including Ginkoba®, Ginsana® and Venastat® which are sold at the nation’s largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin, its products and ongoing programs, please visit www.ilgenetics.com.
# # #
Contacts:
Media:
Catherine Cloft
LaVoie Group
978-745-4200 x107
ccloft@lavoiegroup.com
Investor Relations:
Melanie Friedman
Stern Investor Relations
212-362-1200
melanie@sternir.com